Drug (ID: DG01561) and It's Reported Resistant Information
Name
CCT196969
Synonyms
CCT196969; 1163719-56-9; 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea; CHEMBL4216588; 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea; GTPL9815; SCHEMBL3761639; BCP19551; EX-A1598; BDBM50457449; MFCD28384201; s7743; ZINC43205799; AKOS027422849; CCG-269799; CCT-196969; CS-6229; HY-12846; 1-(3-(t-Butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea; 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido[3,2-b]pyrazin-8-yloxy)phenyl)urea
    Click to Show/Hide
Structure
Target . NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
6
IsoSMILES
CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C(=NC=C3)NC(=O)C=N4)F)C5=CC=CC=C5
InChI
InChI=1S/C27H24FN7O3/c1-27(2,3)21-14-22(35(34-21)16-7-5-4-6-8-16)32-26(37)31-19-10-9-17(13-18(19)28)38-20-11-12-29-25-24(20)30-15-23(36)33-25/h4-15H,1-3H3,(H,29,33,36)(H2,31,32,37)
InChIKey
KYYKGSDLXXKQCR-UHFFFAOYSA-N
PubChem CID
42628843
Type(s) of Resistant Mechanism of This Drug
  EADR: Epigenetic Alteration of DNA, RNA or Protein
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Colorectal cancer [ICD-11: 2B91]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Epigenetic Alteration of DNA, RNA or Protein (EADR) Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [1]
Molecule Alteration Missense mutation
p.V600E (c.1799T>A)
Sensitive Disease Colorectal cancer [ICD-11: 2B91.1]
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model A375 cells Skin Homo sapiens (Human) CVCL_0132
In Vivo Model Female nude mouse xenograft model Mus musculus
Experiment for
Drug Resistance
CellTiter-Glo assay; IC50 assay
Melanoma [ICD-11: 2C30]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Epigenetic Alteration of DNA, RNA or Protein (EADR) Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [2]
Molecule Alteration Missense mutation
p.V600D (c.1799_1800delTGinsAC)
Sensitive Disease Melanoma [ICD-11: 2C30.0]
Experimental Note Identified from the Human Clinical Data
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [1]
Molecule Alteration Missense mutation
p.V600E (c.1799T>A)
Sensitive Disease Melanoma [ICD-11: 2C30.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model A375 cells Skin Homo sapiens (Human) CVCL_0132
In Vivo Model Female xenograft nude mouse model Mus musculus
Experiment for
Molecule Alteration
Western blotting analysis; Sanger Sequencing
Experiment for
Drug Resistance
CellTiter-Glo assay; Tumor volume measurement assay
Key Molecule: GTPase Nras (NRAS) [1]
Molecule Alteration Missense mutation
p.Q61L (c.182A>T)
Sensitive Disease Melanoma [ICD-11: 2C30.0]
Experimental Note Identified from the Human Clinical Data
References
Ref 1 Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaCancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11.
Ref 2 Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibitedCancer Res. 2007 Jan 1;67(1):122-9. doi: 10.1158/0008-5472.CAN-06-1880.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.